Despite their potential, BET inhibitors face several challenges. One significant issue is the development of resistance, which can occur through various mechanisms such as mutations in BET proteins or compensatory activation of alternative survival pathways. Additionally, the toxicities associated with BET inhibition, including fatigue, gastrointestinal disturbances, and thrombocytopenia, can limit their therapeutic window.
